Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

Viking Therapeutics (VKTX) surged 35% after releasing positive maintenance dosing data for VK2735, its dual GLP-1/GIP agonist targeting the $100 billion weight loss drug market. The company is developing both injectable and oral formulations, with the oral version potentially becoming the first of its kind in the dual-agonist category.

VKTX is positioning itself against established players LLY and NVO, which currently dominate the obesity treatment space. The dual mechanism—combining GLP-1 and GIP receptor activation—mirrors the approach of Eli Lilly's successful tirzepatide franchise, but Viking's oral delivery option could differentiate its offering if clinical development continues successfully.

The maintenance dosing data suggests VK2735 can sustain weight loss effects, a critical benchmark for commercial viability in a market where patient adherence and long-term efficacy drive prescribing decisions.